Contents 2 min read

Claim and source comparison

Alpha-GPC: an Alzheimer’s dementia trial, isometric strength and observational stroke data.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

The 2003 trial enrolled 261 people with mild to moderate Alzheimer’s dementia. The trial assigned 132 to 400 mg of choline alfoscerate three times daily and 129 to placebo. At day 180, ADAS-Cog and MMSE scores were better in the choline alfoscerate group.

Scale scores in this patient group do not establish cognitive benefit in healthy people or slower disease progression.

Source 1 · Abstract read

Human randomized controlled trial

In a 2015 crossover trial, 13 young men received 600 mg/day of Alpha-GPC or placebo for 6 days per period. The lower-body isometric force test showed a difference. The difference on the upper-body test was not statistically significant.

This small, short trial did not measure cognition, muscle growth or long-term performance.

Source 3 · Full text read

Human observational study

In a 2021 cohort based on South Korean records for people aged 50 or older, Alpha-GPC prescriptions were associated with stroke. In the matched analysis, the adjusted hazard ratio for all strokes was 1.43 (95% confidence interval 1.41–1.46).

Prescription records may not fully reflect actual use. Underlying health differences could affect the association. This observational estimate does not establish causation or a person’s absolute risk.

Source 6 · Full text read

Our evidence and source methodology

Alpha-GPC: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Alpha-GPC?

Alpha-GPC and CDP-choline are different choline sources. Choline content by weight is not oral bioavailability; a clinical superiority ranking of 88%, 70%, 50% and 20% cannot be verified from these sources.

Mechanism of Effect

Choline is a precursor used in acetylcholine synthesis. The supply of choline from Alpha-GPC does not establish neuroprotection or cognitive improvement in humans.

Clinical Evidence

The 2003 trial enrolled 261 people with mild to moderate Alzheimer’s dementia. The trial assigned 132 to 400 mg of choline alfoscerate three times daily and 129 to placebo. At day 180, ADAS-Cog and MMSE scores were better in the choline alfoscerate group.

Ziegenfuss et al. (2008) published a conference abstract testing 600 mg Alpha-GPC 90 minutes before exercise in 7 men. The 44-fold peak GH rise was relative to baseline, not placebo; peak bench press force was 14% higher than placebo. This small acute study does not establish long-term muscle growth.

In a 2015 crossover trial, 13 young men received 600 mg/day of Alpha-GPC or placebo for 6 days per period. The lower-body isometric force test showed a difference. The difference on the upper-body test was not statistically significant.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

In a 2021 cohort based on South Korean records for people aged 50 or older, Alpha-GPC prescriptions were associated with stroke. In the matched analysis, the adjusted hazard ratio for all strokes was 1.43 (95% confidence interval 1.41–1.46).

Prescription records may not fully reflect actual use. Underlying health differences could affect the association. This observational estimate does not establish causation or a person’s absolute risk.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. De Jesus Moreno Moreno M. (2003). Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics, 25(1), 178–193. PubMed · PMID 12637119
  2. Ziegenfuss T, Landis J, Hofheins J. (2008). Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. Journal of the International Society of Sports Nutrition, 5(Suppl 1), P15. https://doi.org/10.1186/1550-2783-5-S1-P15 Conference poster · Springer Nature
  3. Bellar D, et al. (2015). The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. Journal of the International Society of Sports Nutrition, 12, 42. PubMed · PMID 26582972
  4. Parnetti L, et al. (2007). Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? Journal of the Neurological Sciences, 257(1-2), 264–269. PubMed · PMID 17331541
  5. Canal N, et al. (1991). Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 29(3), 103–107. PubMed · PMID 2071257
  6. Lee G, et al. (2021). Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Network Open, 4(11), e2136008. https://doi.org/10.1001/jamanetworkopen.2021.36008 PubMed · PMID 34817582

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions